Industries > Pharma > Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 06 April 2021
PAGES: 332
PRODUCT CODE: PHA1124
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1124 Categories: , Tag:

Inflammatory Bowel Disease Drugs Market – reveals latest opportunities, trends, projected revenues, and competitive landscape. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.

Global inflammatory bowel disease drugs market is projected to reach a market value of US$xxbillion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis and growing investment in R&D by pharmaceutical companies are major factor that drives the demand for IBD drugs. Some other key factors that propel the market growth are the growing adoption of drugs for inflammatory bowel disease treatment and maintenance therapy; rising awareness for Crohn’s disease and ulcerative colitis in developing countries; and technological advancements. In addition, the COVID-19 pandemic has a significant impact on the IBD drugs market.

Visiongain’s report shows you the potential revenue streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the inflammatory bowel disease drugs industry.

How this report will benefit you
Visiongain’s 330+ page report provides 199 tables and 147 charts/graphs. Our new study is envisioned for anyone requiring commercial in-depth analyses for the global IBD drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for IBD drugs. Get the financial analysis of the overall market and different segments including drug class, indication, patient demographics, end-user, and distribution channel and capture higher market share. High opportunity remains in this fast-growing inflammatory bowel disease drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

Forecasts to 2031 and other analyses reveal the commercial prospects
• Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
• It also includes growth rates for different 4 regional markets along with 11 countries and COVID-19 impact analysis on each market
• The profiles of the top 13 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
• The COVID-19 has a positive impact on the IBD drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.

Discover sales forecasts for the global and regional market forecasts from 2021-2031
Along with revenue prediction for the overall global inflammatory bowel disease market, there is segmentation by region for 4 regional markets including the U.S., Japan, Europe5, BRIC, and RoW and 11 major countries.

To access the data contained in this document please email contactus@visiongain.com

CTA

Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class
• Biologics
• Aminosalicylates
• Corticosteroids
• Antibiotics
• Immunomodulators
• Others

Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Indication
• Crohn’s Disease
• Ulcerative Colitis

Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Regional market revenue and growth forecasts from 2021 to 2031:

• U.S.

• Japan

• Europe5
• Germany
• UK
• France
• Italy
• Spain

• BRIC
• Brazil
• Russia
• India
• China

• RoW

Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Need industry data? Please contact us today.

Detailed profiles of 13 leading companies that are operating in the market
The report includes profiles of 13 major companies involved in the IBD drugs market. The companies profiled in this report include: AbbVie, Janssen Biotech, Allergan plc., Takeda Pharmaceuticals, Pfizer Inc., Novartis AG, UCB Pharma S.A., Biogen Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Celgene Corporation, Celltrion Corporation, and Ferring B.V.

Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

In summary, our 330+ page report delivers you with the following knowledge:
• Revenue forecasts from 2021 to 2031 for the global IBD drugs market and subsegments (by drug class, indication, distribution channel, and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
• Detailed profiles of top 13 IBD drugs manufacturers, with financial overviews
• Revenue forecasts from 2021 to 2031 for 4 regional markets – See forecasts for the IBD drugs market in the U.S., Japan, Europe5, BRIC, and RoW.

Information found nowhere else
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the IBD drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.

The Inflammatory Bowel Disease Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the IBD drugs industry.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031


Download sample pages

Complete the form below to download your free sample pages for Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories